A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF COMBINATIONS OF REGN2810 (ANTI-PD-1 ANTIBODY), PLATINUM-BASED DOUBLET CHEMOTHERAPY, AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) VERSUS PEMBROLIZUMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH TUMORS EXPRESSING PD-L1 50%
Study of Combinations of REGN2810, Chemotherapy, and Ipilimumab vs. Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
Sponsor: Regeneron Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR7798
Contact: Naiyer Rizvi, MD: 212-305-5098 / nar2144@cumc.columbia.edu
Additional Study Information: This study is being done to determine if REGN2810 (anti-PD-1) in combination with ipilimumab (anti-CTLA-4) plus initial platinum-based doublet chemotherapy, or REGN2810 in combination with ipilimumab will prolong how long you live without your disease progressing compared to the standard of care pembrolizumab (anti-PD-1) monotherapy treatment. Neither REGN2810 nor ipilimumab monotherapy are approved for NSCLC by Health Authorities, such as the U.S. Food and Drug Administration (FDA).
This study is closed
Investigator
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with non-small cell lung cancer (NSCLC)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Naiyer Rizvi, MD
nar2144@cumc.columbia.edu
212-305-5098
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE